Q2 Earnings Forecast for ACRS Issued By Lifesci Capital

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities research analysts at Lifesci Capital issued their Q2 2026 earnings per share estimates for shares of Aclaris Therapeutics in a research note issued on Monday, June 1st. Lifesci Capital analyst K. Dellorusso anticipates that the biotechnology company will post earnings of ($0.17) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.62) per share. Lifesci Capital also issued estimates for Aclaris Therapeutics’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.79) EPS, Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.65) EPS.

A number of other research analysts also recently weighed in on the company. Oppenheimer assumed coverage on Aclaris Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating and a $10.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research note on Thursday, March 19th. Guggenheim assumed coverage on Aclaris Therapeutics in a research note on Tuesday, May 5th. They set a “buy” rating and a $12.00 price target on the stock. Piper Sandler upped their price target on Aclaris Therapeutics from $7.00 to $11.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Friday, March 27th. Three equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $11.50.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS opened at $4.42 on Thursday. The company has a market capitalization of $617.30 million, a price-to-earnings ratio of -7.89 and a beta of 0.76. The business’s 50-day moving average is $4.29 and its 200-day moving average is $3.57. Aclaris Therapeutics has a 1 year low of $1.34 and a 1 year high of $5.15.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 55.89% and a negative net margin of 832.58%.The firm had revenue of $2.00 million for the quarter, compared to analyst estimates of $1.32 million.

Insider Buying and Selling

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard sold 300,000 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $4.53, for a total transaction of $1,359,000.00. Following the completion of the sale, the insider directly owned 13,950,000 shares of the company’s stock, valued at approximately $63,193,500. The trade was a 2.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Aclaris Therapeutics

Several institutional investors have recently modified their holdings of ACRS. Bank of New York Mellon Corp raised its position in shares of Aclaris Therapeutics by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company’s stock worth $776,000 after buying an additional 3,507 shares in the last quarter. Raymond James Financial Inc. raised its position in shares of Aclaris Therapeutics by 2.2% in the third quarter. Raymond James Financial Inc. now owns 283,476 shares of the biotechnology company’s stock worth $539,000 after buying an additional 6,217 shares in the last quarter. Rhumbline Advisers raised its position in shares of Aclaris Therapeutics by 7.4% in the third quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock worth $173,000 after buying an additional 6,271 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Aclaris Therapeutics by 45.4% in the fourth quarter. ProShare Advisors LLC now owns 21,553 shares of the biotechnology company’s stock worth $65,000 after buying an additional 6,734 shares in the last quarter. Finally, Intech Investment Management LLC raised its position in shares of Aclaris Therapeutics by 19.8% in the fourth quarter. Intech Investment Management LLC now owns 46,646 shares of the biotechnology company’s stock worth $140,000 after buying an additional 7,702 shares in the last quarter. 98.34% of the stock is owned by institutional investors.

Key Stories Impacting Aclaris Therapeutics

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: Lifesci Capital initiated coverage on Aclaris Therapeutics with an “Outperform” rating and a $13 price target, implying substantial upside versus the recent share price. Benzinga report on Lifesci Capital coverage
• Positive Sentiment: The firm later upgraded Aclaris to “Strong-Buy”, reinforcing the positive sentiment around the stock. Zacks report on Aclaris upgrade
• Neutral Sentiment: Lifesci Capital also released multiple earnings estimates, including FY2026 EPS of ($0.79) and FY2027 EPS of ($1.65), indicating continued expected losses but with a detailed long-term forecast.
• Neutral Sentiment: The analyst maintained a consistent set of quarterly estimates for 2026–2027, with quarterly EPS losses ranging from $(0.17) to $(0.46), which mostly updates expectations rather than changing the overall story.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.